Shearman & Sterling advised Bank of America Merrill Lynch, Morgan Stanley and China Merchant Securities as joint sponsors, joint global coordinators and joint bookrunners on the US$510 million global offering and initial public offering of WuXi Biologics (Cayman) Inc. (WuXi Biologics) on the Main Board of The Stock Exchange of Hong Kong Limited.
The completion of WuXi Biologics’ Hong Kong listing marked the second Chinese company to relist in Hong Kong after going private in the United States. WuXi PharmaTech (Cayman) Inc., the parent company of WuXi Biologics, was delisted from the United States in December 2015 through a US$3.3 billion management buyout.
WuXi Biologics is a global leading biologics services provider offering discovery, development and manufacturing of biologics services to pharmaceutical and biotechnology companies. It is the only open-access biologics technology platform in the world offering end-to-end solutions to empower any interested parties to discover, develop and manufacture biologics from conception of an idea to finally achieving commercial manufacturing.